Ignite Creation Date:
2025-12-25 @ 1:25 AM
Ignite Modification Date:
2026-04-08 @ 9:24 AM
Study NCT ID:
NCT01903993
Status:
COMPLETED
Last Update Posted:
2019-10-02
First Post:
2013-07-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-08-06
Start Date Type:
ACTUAL
Primary Completion Date:
2015-11-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-09-06
Completion Date Type:
ACTUAL
First Submit Date:
2013-07-17
First Submit QC Date:
None
Study First Post Date:
2013-07-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-11-16
Results First Submit QC Date:
None
Results First Post Date:
2017-05-23
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2016-06-20
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2019-09-10
Last Update Post Date:
2019-10-02
Last Update Post Date Type:
ACTUAL